IMMIX BIOPHARMA, INC.

(IMMX)
Delayed Nasdaq  -  05/19 04:00:00 pm EDT
1.630 USD   +25.38%
05/13IMMIX BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)
AQ
05/13Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/09Immix Biopharma Announces Share Repurchase Program
AQ
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Immix Biopharma Shares Soar Premarket After Key FDA Designation

01/03/2022 | 08:59am EDT

By Colin Kellaher

Shares of Immix Biopharma Inc. surged more than 50% in premarket trading Monday after the clinical-stage biopharmaceutical company received a key U.S. Food and Drug Administration designation for its lead product candidate.

The Los Angeles company said the FDA granted rare-pediatric-disease designation to IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening form of pediatric cancer.

Drugmakers who eventually win FDA approval of a drug granted the rare-pediatric-disease designation receive priority-review vouchers, which they can use to obtain priority review for another drug or sell to other companies.

Mirum Pharmaceuticals Inc. last year received a priority-review voucher upon FDA approval of its cholestatic pruritus drug Livmarli for patients with Alagille syndrome and later agreed to sell the voucher for $110 million.

Immix shares, which closed Friday at $3.56, were recently up 55% at $5.50 in premarket trading. The company went public last month at $5 a share.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

01-03-22 0859ET

Stocks mentioned in the article
ChangeLast1st jan.
IMMIX BIOPHARMA, INC. 25.38% 1.63 Delayed Quote.-63.48%
MIRUM PHARMACEUTICALS, INC. 5.49% 24.21 Delayed Quote.43.89%
All news about IMMIX BIOPHARMA, INC.
05/13IMMIX BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/13Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
05/09Immix Biopharma Announces Share Repurchase Program
AQ
05/09Immix Biopharma, Inc. authorizes a Buyback Plan.
CI
05/09Immix Biopharma, Inc. announces an Equity Buyback for $1 million worth of its shares.
CI
04/05ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX A..
AQ
03/28IMMIX BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
03/28Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 202..
CI
03/20IMMIX BIOPHARMA, INC.(NASDAQCM : IMMX) added to S&P TMI Index
CI
03/07Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022
AQ
More news
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 18,1 M 18,1 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees 2
Free-Float 75,0%
Chart IMMIX BIOPHARMA, INC.
Duration : Period :
Immix Biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMIX BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Ilya Rachman Chairman & Chief Executive Officer
Gabriel A. Morris Chief Financial Officer & Director
Graham Ross Chief Medical Officer & Head-Clinical Development
Helen C. Adams Independent Director
Jane Melissa Buchan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMIX BIOPHARMA, INC.-63.48%18
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-19.12%41 409
BIONTECH SE-39.08%38 169